跳至主要内容
临床试验/JPRN-UMIN000021267
JPRN-UMIN000021267已完成未知

ongitudinal Efficacy and Safety Study of Tolvaptan on Autosomal Dominant Polycystic Kidney Disease Patients - Efficacy Study of Tolvaptan on ADPKD Patients [LET-PKD study]

Autosomal Dominant Polycystic Kidney Disease Research Section, Kyorin University, School of Medicine0 个研究点目标入组 119 人开始时间: 2016年3月12日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
119

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Patients who have been taking tolvaptan since the TEMPO study 2) Patients who are not eligible, at the discretion of Kyorin University Hospital, to take tolvaptan for the stated indication according to the criteria for careful administration of Samsca as specified by the Ministry of Health, Labour and Welfare - Patients with a history of hypersensitivity to tolvaptan or similar chemical compounds - Patients who do not feel thirsty or have difficulty swallowing water - Patients with hypernatremia - Patients with eGFR less than 15 mL/min/1.73 m2 - Patients with chronic hepatitis, drug-induced hepatic dysfunction or other hepatic dysfunctions - Pregnant women or women suspected of being pregnant. Female patients who wish to become pregnant

研究者

发起方
Autosomal Dominant Polycystic Kidney Disease Research Section, Kyorin University, School of Medicine

相似试验

ongitudinal Efficacy and Safety Study of Tolvaptan... | 临床试验